Home/Partnering with the Patient Community

Partnering with the Patient Community

We connect with patient groups, health experts, and governments to better understand patient needs to inform and develop tools and programs to support optimal care for patients.

At Johnson & Johnson, we recognise the importance of partnership and collaboration across the healthcare ecosystem to achieve our goal of providing optimal care for patients. Applying rigorous science and care, we address some of the most complex diseases of our time to unlock the potential medicines of tomorrow.

To do this, we must deeply understand patients' needs and engage with the patient community to find solutions that have the highest health impact. We actively engage with healthcare experts, the patient community and governments to gain a deeper understanding of the unique needs and challenges faced by patients. We know that sustained engagement is vital to making a meaningful impact. Through ongoing dialogue and collaboration, we strive to put patients at the center of our healthcare system and consider their individual needs as human beings.

We believe we have an important role to play. In Australia we partner with a diverse range of organisations. Many of our relationships are long-standing, some over 20 years and we continue to forge new connections that broaden our impact. We are committed to supporting those who need it most.

How we partner

We sat down with leaders from advocacy groups to get their thoughts on the current state of patient centricity in healthcare. What does it truly mean for science and care to come together to support patients? What are we doing and what could we do in the future? From the quality of information available to involvement in decision making hear what matters most for our patient communities.

Partnerships play a crucial role in driving positive change, particularly when it comes to enhancing health outcomes. Johnson & Johnson collaborates with a diverse range of organisations, allowing us to tackle pressing health issues more effectively. We believe this helps us reach a broad range of stakeholders and provide vital support where it's needed most.

Through these partnerships, we can develop innovative solutions and expand the scope of our impact, resulting in improved health outcomes for individuals and families. The question remains: why is partnering so important? Simply put, it allows us to leverage collective strengths to create a healthier, more equitable society for all.

The Lymphoma Nurse education program enabled us to ensure blood cancer nurses receive current and balanced information so we can empower them to improve patients' lives. Our patients benefit from our partnership with Johnson & Johnson by being able to access better care, know more about clinical trials and understand the real-world data that is happening around all the world and maybe not happening in Australia.

Sharon Winton, CEO, Lymphoma Australia

We are united in the mission to improve and facilitate earlier diagnosis and empower patients to manage their lives and treatments better. Our partnership with Johnson & Johnson is a tangible example of the real impact we can make where it matters most. For more than five years we advocated for the National Targeted Lung Cancer Screening Program to help improve the outcomes for Australia’s biggest cancer killer – lung cancer – and in May 2023 we achieved that goal.

Mark Brooke, CEO, Lung Foundation Australia

Our virtual education series are a true example of the impact our partnerships can make on the community. Working with Johnson & Johnson, we developed a range of resources to support people living with scleroderma in managing their condition. We implemented a monthly education session to reach members who may be excluded from face to face events particularly during the pandemic. We know by educating the community about their health can promote better outcomes.

Amanda Lawrie-Jones, Chair of the Board, Scleroderma Australia

We know that shared decision-making is critical for patients especially those living with a chronic condition such as Multiple Myleoma. However, most appointments have a limited timeframe that can make it challenging to ask the right questions. We created the ChoiceApp to help facilitate treatment discussions between people living with multiple myleoma and their healthcare team. It was designed in collaboration with Myeloma Australia, with support from Johnson & Johnson, and is based on extensive research with patients, carers and healthcare professionals. Filling in ChoiceApp prior to their appointment not only helps the person and their family feel organised but it helps the doctor to focus on what's most important to that person.

Hayley Beer, Lead Stakeholder Engagement and Advocacy, Myeloma Australia

Our partners